Home » Stocks » BMY

Bristol-Myers Squibb Company (BMY)

Stock Price: $64.44 USD -0.39 (-0.60%)
Updated Jan 26, 2021 4:00 PM EST - Market closed
After-hours: $64.35 -0.09 (-0.14%) Jan 26, 7:55 PM
Market Cap 146.50B
Revenue (ttm) 39.40B
Net Income (ttm) -44.00M
Shares Out 2.25B
EPS (ttm) -0.02
PE Ratio n/a
Forward PE 8.79
Dividend $1.96
Dividend Yield 3.04%
Trading Day January 26
Last Price $64.44
Previous Close $64.83
Change ($) -0.39
Change (%) -0.60%
Day's Open 64.50
Day's Range 64.38 - 65.65
Day's Volume 11,284,071
52-Week Range 44.97 - 66.74

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
The Motley Fool - 14 hours ago

Here's what the Oracle of Omaha is betting on for the coming year.

Other stocks mentioned: AAPL, ABBV, BAC, GS, JPM, KO, MRK, WFC
Zacks Investment Research - 1 day ago

Bristol-Myers Squibb (BMY) closed the most recent trading day at $64.83, moving +0.42% from the previous trading session.

The Motley Fool - 2 days ago

The future is bright for these three companies and investors who buy today could win big.

Other stocks mentioned: LLY, VEEV
The Motley Fool - 2 days ago

Here's your roadmap to building wealth under the new administration.

Other stocks mentioned: BRK.A, BRK.B, CRWD, FSLY, USB
Business Wire - 4 days ago

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #BMS--US FDA Approves OPDIVO in Combination with CABOMETYX as First-line Treatment for Patients with Advanced Renal Cell Carcinoma

Zacks Investment Research - 4 days ago

Bristol-Myers (BMY) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

The Motley Fool - 4 days ago

Both have the potential to drive solid returns in 2021.

Other stocks mentioned: PINS
Zacks Investment Research - 5 days ago

Bristol Myers' (BMY) sBLA for the label expansion of Opdivo for gastric cancer, gastroesophageal junction cancer or esophageal adenocarcinoma gets priority review.

Business Wire - 5 days ago

NEW YORK--(BUSINESS WIRE)--Bristol Myers Squibb Announces Earnings Call Time Change; Fourth Quarter 2020 Earnings Call to Occur on February 4, 2021 at 10 a.m. (Eastern Time)

Business Wire - 6 days ago

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #BMS--US FDA Accepts for Priority Review Application for Opdivo Combined with Chemotherapy as First-Line Treatment in Metastatic Gastric Cancer....

Business Wire - 6 days ago

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #BMS--U.S. FDA Accepts for Priority Review Application for Opdivo as Adjuvant Therapy for Patients w/Resected Esophageal or Gastroesophageal Junction ...

The Motley Fool - 1 week ago

These drug approvals will help the smaller biotech co-developers.

GuruFocus - 1 week ago

Seattle-based Sana Biotechnology is shooting to raise $150 million in its initial public offering, but soon after is expected to see its market value to soar to more than $10 billion, accordin...

Zacks Investment Research - 1 week ago

Bristol-Myers Squibb (BMY) closed the most recent trading day at $66.54, moving +0.79% from the previous trading session.

Seeking Alpha - 1 week ago

Bristol presented at the JPMorgan conference earlier this week. For the first time, BMY has provided long-term revenue and margin guidance.

GuruFocus - 1 week ago

With plenty of cash squirreled away, Bristol-Myers Squibb Co. (NYSE:BMY) is looking to make more acquisitions, CEO Giovanni Caforio, M.D., said at the annual J.P.

The Motley Fool - 1 week ago

Those are some solid endorsements.

Other stocks mentioned: JNJ, NVS, NVTA, RHHBY
The Motley Fool - 1 week ago

High dividend yields plus low valuations could be just the ticket for income-seeking investors.

Other stocks mentioned: ABBV, VTRS
InvestorPlace - 1 week ago

Pharmaceutical stocks have many benefits, particularly when their products are in demand. And in 2021, that seems likely to be the case.

Other stocks mentioned: ABBV, ELAN, JAZZ, JNJ, MRNA, PFE
Zacks Investment Research - 2 weeks ago

Bristol-Myers Squibb (BMY) closed the most recent trading day at $65.43, moving +0.71% from the previous trading session.

Bloomberg Markets and Finance - 2 weeks ago

Bristol-Meyers Squibb CEO on Covid-19, Political Contributions

Jan.12 -- Bristol-Meyers Squibb Chief Executive Officer Giovanni Cafario discusses the overall impact of Covid-19 on the healthcare industry, remaining focused on innovation, and pausing contr...

CNBC Television - 2 weeks ago

Bristol Myers Squibb CEO expects Zeposia to renew company's medicine portfolio

"Zeposia is one of the key medicines that we count on for the renewal of our portfolio, and things are progressing very well," Bristol-Myers Squibb CEO Giovanni Caforio said of the phase three...

The Motley Fool - 2 weeks ago

With solid valuations and good dividends, these businesses will get you through the next rainy day -- or year.

Other stocks mentioned: JNJ, MPW
The Motley Fool - 2 weeks ago

The company's total authorization now stands at around $6.4 billion.

InvestorPlace - 2 weeks ago

Pharmaceutical stocks can be a great investment in a unique niche of the market. The stocks on this list will be strong for a decade plus.

Other stocks mentioned: ABBV, JNJ, NVS, PFE, SNY, TAK
Seeking Alpha - 2 weeks ago

Bristol-Myers Squibb Company's (BMY) CEO Giovanni Caforio Presents at 39th Annual JPMorgan Virtual Healthcare Conference - (Transcript)

Business Wire - 2 weeks ago

MENLO PARK, Calif.--(BUSINESS WIRE)--GRAIL, Inc., a healthcare company whose mission is to detect cancer early, today announced collaborations with global biopharmaceutical companies Amgen (NA...

Other stocks mentioned: AMGN, AZN
Market Watch - 2 weeks ago

Bristol Myers Squibb Co. said Monday its board has approved an additional $2 billion of share buybacks, bringing the company's full authorization to about $6.4 billion. Shares rose 1% premarke...

Business Wire - 2 weeks ago

NEW YORK--(BUSINESS WIRE)--Bristol Myers Squibb Announces $2 Billion Incremental Share Repurchase Authorization

The Motley Fool - 2 weeks ago

An attractive price and dividend combined with tremendous growth prospects make this stock a slam-dunk buy.

The Motley Fool - 2 weeks ago

Each of them should have positive catalysts in the new year.

Other stocks mentioned: AAPL, MA
The Motley Fool - 2 weeks ago

They all pay more than the 3% yield you can expect from the soft-drink giant.

Other stocks mentioned: RY, VZ, VZA
Zacks Investment Research - 2 weeks ago

In the latest trading session, Bristol-Myers Squibb (BMY) closed at $61.70, marking a +0.24% move from the previous day.

Seeking Alpha - 3 weeks ago

This article is about reviewing 2020 as a complete year from the lens of dividend growth/dividend investing. My portfolio holds a large variety of exposures in a multitude of geographies, sect...

Other stocks mentioned: INTC, PRU, T
Accesswire - 3 weeks ago

ADDING ANOTHER DRUG DISCOVERY PROJECT TO THE PORTFOLIO TRIGGERS PAYMENT TO EVOTEC HAMBURG, GERMANY / ACCESSWIRE / January 5, 2021 / Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN:...

InvestorPlace - 3 weeks ago

2020 has taken the market capitalizations of many strong companies to lows. That means there are some great options for cheap stocks to buy in January.

Other stocks mentioned: ABBV, APTV, DIS, HHC, INTC, LUV
Business Wire - 3 weeks ago

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #BMS--European Medicines Agency Validates Bristol Myers Squibb's Application for Opdivo (nivolumab) as Adjuvant Treatment for....

Business Wire - 3 weeks ago

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #BMS--European Medicines Agency Validates Bristol Myers Squibb's Application for Opdivo (nivolumab) Combined with Chemotherapy as First-Line Treatment...

Business Wire - 3 weeks ago

NEW YORK--(BUSINESS WIRE)--Bristol Myers Squibb to Present at J.P. Morgan's 39th Annual Virtual Healthcare Conference

The Motley Fool - 3 weeks ago

All of them should be long-term winners.

Other stocks mentioned: BAC, BRK.A, BRK.B
Business Wire - 3 weeks ago

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #BMS--Bristol Myers Squibb Provides Update on Status of Contingent Value Rights

Seeking Alpha - 3 weeks ago

2021 could be a year in which value stocks outperform. Income potential remains a key theme for 2021 and beyond, as interest rates remain at record lows.

Other stocks mentioned: ABBV, C, EPD, INTC, MPLX, PRU, SPG, SPY, T, WPC
InvestorPlace - 3 weeks ago

Cheap stocks have always intrigued investors because we always want a bargain. So, here are seven cheap stocks to buy now.

Other stocks mentioned: ALLY, BABA, GOGO, QCOM, T, WBA
Zacks Investment Research - 3 weeks ago

Investors need to pay close attention to Bristol-Myers Squibb (BMY) stock based on the movements in the options market lately.

24/7 Wall Street - 3 weeks ago

With 2020 mercifully ending today, many investors are evaluating portfolios for 2021.

Other stocks mentioned: AVGO, CMCSA, ETN, NOC
Zacks Investment Research - 3 weeks ago

In the latest trading session, Bristol Myers Squibb (BMY) closed at $61.92, marking a +0.81% move from the previous day.

Seeking Alpha - 3 weeks ago

The elusive conjunction of safety and growing yield is a holy grail for many investors. Seeking Alpha's quant system screens seven larger large cap biotech stocks with dividends ranging from 3...

Other stocks mentioned: ABBV
Seeking Alpha - 4 weeks ago

Undervalued Pharmaceutical Dividends For The New Year

Other stocks mentioned: ABBV, JNJ, PFE
Zacks Investment Research - 4 weeks ago

Bristol Myers' (BMY) MAA for Zeposia for the treatment of adults with moderately to severely active ulcerative colitis gets validated by EMA.

Seeking Alpha - 4 weeks ago

Dividend Changes: December 19-25, 2020

Other stocks mentioned: BEN, BFC, CSCO, ITW, JPM, MAIN, O, ORCL, SFBS, SYK, WPC

About BMY

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products in hematology, oncology, cardiovascular, and immunology therapeutic classes. The company's products include Opdivo for anti-cancer indications; Eliquis, an oral inhibitor targeted at stroke prevention in adult patients with non-valvular atrial fibrillation, and the prevention and treatment of venous thromboembolic disorders; and Orencia for adult patients with active RA and prostate-specific antigen, as ... [Read more...]

Industry
Drug Manufacturers-General
Founded
1887
CEO
Giovanni Caforio
Employees
30,000
Stock Exchange
NYSE
Ticker Symbol
BMY
Full Company Profile

Financial Performance

In 2019, BMY's revenue was $26.15 billion, an increase of 15.89% compared to the previous year's $22.56 billion. Earnings were $3.44 billion, a decrease of -30.10%.

Financial Statements

Analyst Forecasts

According to 19 analysts, the average rating for BMY stock is "Buy." The 12-month stock price forecast is 74.88, which is an increase of 16.20% from the latest price.

Price Target
$74.88
(16.20% upside)
Analyst Consensus: Buy